FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000548391> ?p ?o ?g. }

• W2000548391 endingPage "591" @default.
• W2000548391 startingPage "585" @default.
• W2000548391 abstract "The aim of this study was to assess the long-term safety and efficacy of glatiramer acetate (GA) for patients with multiple sclerosis (MS) who received active treatment versus those on placebo for approximately 30 months (24-35 months) before receiving GA during a six-year organized, prospective open label study. Entry required two relapses in the previous two years and an Expanded Disability Status Scale (EDSS) score of 0-5. Patients (251) were equally randomized to daily subcutaneous GA, 20 mg, or to placebo. After approximately 30 months, 208 patients continued in an open label study: 101 continued on GA and 107 switched from placebo to active drug. Groups were well matched at randomization and entry to the open label study. Patients always on GA showed a steady decline in relapses: a mean of 1.5 per year at entry, a mean of 0.42 over the entire six years (95% CI = 0.34-0.51), a 72% reduction (P = 0.0001). They averaged a relapse every four + years (yearly rate 0.23 in year six) and 26/101 remain relapse free. Patients did less well if on placebo for 30 months, but relapses then declined, and by year six the rates were similar. Of patients always on GA, 69% showed neurological improvement of > or = 1 EDSS steps or remained stable compared with 57% if GA treatment was delayed. Of relapse-free patients always on GA over six years, only three of 26 (11%) were worse by > or = 1 EDSS steps, whereas nine of 21 (43%) in the placebo/active group were worse (P < 0.03). Disability, measured every six months, showed that the group of patients always on GA was relatively stable over the six years, while the group who received placebo for the first two-and-a-half years did significantly less well. Daily injections of GA were well tolerated. This longest ever organized MS treatment trial shows that delaying therapy with GA increases the risk of neurologic disability, reinforcing the rationale for using GA as a first-line treatment early in the course of relapsing-remitting MS." @default.
• W2000548391 created "2016-06-24" @default.
• W2000548391 creator A5008779076 @default.
• W2000548391 creator A5009994219 @default.
• W2000548391 creator A5010540807 @default.
• W2000548391 creator A5016495852 @default.
• W2000548391 creator A5018098296 @default.
• W2000548391 creator A5037675795 @default.
• W2000548391 creator A5044785309 @default.
• W2000548391 creator A5056259938 @default.
• W2000548391 creator A5067116063 @default.
• W2000548391 creator A5076338840 @default.
• W2000548391 creator A5078352587 @default.
• W2000548391 date "2003-12-01" @default.
• W2000548391 modified "2023-09-26" @default.
• W2000548391 title "Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial" @default.
• W2000548391 cites W1967507425 @default.
• W2000548391 cites W1983757159 @default.
• W2000548391 cites W2005506388 @default.
• W2000548391 cites W2020047554 @default.
• W2000548391 cites W2054531003 @default.
• W2000548391 cites W2103255085 @default.
• W2000548391 cites W2112165124 @default.
• W2000548391 cites W2127671643 @default.
• W2000548391 cites W2332846030 @default.
• W2000548391 cites W2984556666 @default.
• W2000548391 cites W3026077775 @default.
• W2000548391 cites W4234254101 @default.
• W2000548391 cites W4244028742 @default.
• W2000548391 cites W4366064463 @default.
• W2000548391 cites W4376522286 @default.
• W2000548391 doi "https://doi.org/10.1191/1352458503ms961oa" @default.
• W2000548391 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14664471" @default.
• W2000548391 hasPublicationYear "2003" @default.
• W2000548391 type Work @default.
• W2000548391 sameAs 2000548391 @default.
• W2000548391 citedByCount "54" @default.
• W2000548391 countsByYear W20005483912012 @default.
• W2000548391 countsByYear W20005483912013 @default.
• W2000548391 countsByYear W20005483912014 @default.
• W2000548391 countsByYear W20005483912015 @default.
• W2000548391 countsByYear W20005483912016 @default.
• W2000548391 countsByYear W20005483912017 @default.
• W2000548391 countsByYear W20005483912018 @default.
• W2000548391 countsByYear W20005483912019 @default.
• W2000548391 countsByYear W20005483912020 @default.
• W2000548391 countsByYear W20005483912022 @default.
• W2000548391 crossrefType "journal-article" @default.
• W2000548391 hasAuthorship W2000548391A5008779076 @default.
• W2000548391 hasAuthorship W2000548391A5009994219 @default.
• W2000548391 hasAuthorship W2000548391A5010540807 @default.
• W2000548391 hasAuthorship W2000548391A5016495852 @default.
• W2000548391 hasAuthorship W2000548391A5018098296 @default.
• W2000548391 hasAuthorship W2000548391A5037675795 @default.
• W2000548391 hasAuthorship W2000548391A5044785309 @default.
• W2000548391 hasAuthorship W2000548391A5056259938 @default.
• W2000548391 hasAuthorship W2000548391A5067116063 @default.
• W2000548391 hasAuthorship W2000548391A5076338840 @default.
• W2000548391 hasAuthorship W2000548391A5078352587 @default.
• W2000548391 hasConcept C126322002 @default.
• W2000548391 hasConcept C141071460 @default.
• W2000548391 hasConcept C142724271 @default.
• W2000548391 hasConcept C168563851 @default.
• W2000548391 hasConcept C203014093 @default.
• W2000548391 hasConcept C204243189 @default.
• W2000548391 hasConcept C204787440 @default.
• W2000548391 hasConcept C27081682 @default.
• W2000548391 hasConcept C2778577042 @default.
• W2000548391 hasConcept C2780640218 @default.
• W2000548391 hasConcept C2780892749 @default.
• W2000548391 hasConcept C71924100 @default.
• W2000548391 hasConceptScore W2000548391C126322002 @default.
• W2000548391 hasConceptScore W2000548391C141071460 @default.
• W2000548391 hasConceptScore W2000548391C142724271 @default.
• W2000548391 hasConceptScore W2000548391C168563851 @default.
• W2000548391 hasConceptScore W2000548391C203014093 @default.
• W2000548391 hasConceptScore W2000548391C204243189 @default.
• W2000548391 hasConceptScore W2000548391C204787440 @default.
• W2000548391 hasConceptScore W2000548391C27081682 @default.
• W2000548391 hasConceptScore W2000548391C2778577042 @default.
• W2000548391 hasConceptScore W2000548391C2780640218 @default.
• W2000548391 hasConceptScore W2000548391C2780892749 @default.
• W2000548391 hasConceptScore W2000548391C71924100 @default.
• W2000548391 hasIssue "6" @default.
• W2000548391 hasLocation W20005483911 @default.
• W2000548391 hasLocation W20005483912 @default.
• W2000548391 hasOpenAccess W2000548391 @default.
• W2000548391 hasPrimaryLocation W20005483911 @default.
• W2000548391 hasRelatedWork W160847151 @default.
• W2000548391 hasRelatedWork W1905950082 @default.
• W2000548391 hasRelatedWork W2058632873 @default.
• W2000548391 hasRelatedWork W2108738499 @default.
• W2000548391 hasRelatedWork W2172096346 @default.
• W2000548391 hasRelatedWork W2283616019 @default.
• W2000548391 hasRelatedWork W2331541024 @default.
• W2000548391 hasRelatedWork W2489457358 @default.
• W2000548391 hasRelatedWork W2555342887 @default.
• W2000548391 hasRelatedWork W2895976370 @default.

• next